NCT04080024View on ClinicalTrials.gov

A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 23, 2019

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Breast CancerPancreas Cancer
Interventions
DRUG

SN132D

Novel manganese-based macromolecular MRI contrast agent

Trial Locations (2)

SE-41345

Gothia Forum Clinical Trial Center, Gothenburg

SE-75185

CTC Clinical Trial Consultants AB, Uppsala

Sponsors
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

collaborator

Antaros Medical

INDUSTRY

lead

Spago Nanomedical AB

INDUSTRY